318
Views
16
CrossRef citations to date
0
Altmetric
MOUTH/PHARYNX

Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer

, , , &
Pages 1108-1114 | Received 09 Feb 2012, Accepted 08 Apr 2012, Published online: 21 Sep 2012

References

  • Holland JC, Rowland JH. 1989. Handbook of psycho-oncology: psychological care of the patient with cancer. New York: Oxford University Press. p 135–9.
  • Furusaka T, Matsuda H, Tanaka A, Ikeda M. 2010. Combination of superselective arterial injection chemotherapy and radiation therapy for tongue squamous cell carcinoma. IFNHOS 2010, Seoul, Abstract Book. p 212.
  • Furusaka T. [Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer – for tongue cancer patients in comparison patients with other therapies]. Gan To Kagaku Ryoho 2006;33:1241–6; (in Japanese).
  • Furusaka T, Asakawa T, Sekine H, Matuzaki H, Ikeda M. Superselective intra-arterial chemotherapy and superselective intra-arterial chemotherapy with concomitant radiation therapy for squamous cell carcinoma of the tongue. Stomato-pharyngology 2010;23:243–7; (in Japanese).
  • Furusaka T, Kida A, Kukimoto N, Yokode Y, Horikawa Y, Makiyama K, Combination chemotherapy with cyclophosphamide C, adriamycin (A), cis-platinumdiamminedichloride (P) in head and neck malignant tumor – one day CAP regimen. Otologia 1985;31:471–7.
  • Furusaka T, Kida A, Aoyagi M, Makiyama K, Iida H, Miyakogawa M, CAP therapy for advanced, recurrent and/or metastatic malignant tumors of the head and neck. Auris Nasus Larynx 1986;13(Suppl 1):S119–26.
  • Furusaka T, Kida A, Iida H, Yokode Y, Kikuchi K, Tomita H. Combination chemotherapy with CDDP and 5-FU in head and neck cancer. Auris Nasus Larynx 1986;13(Suppl 1):S127–33.
  • Taguchi T, Furue H, Niitani H, Ishitani K, Kanamaru R. Ariyoshi, et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho 1984;21:1997–2005.
  • Pignon JP, Syz N, Posner M, Olivares R, Le Lann L, Yver A, Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004;15:331–40.
  • Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. ASCO Annual Meeting Proceedings 2006;24(18S):5506.
  • Vermorken JB, Remenar E, Herpen VC, Gorlia T, Mesia R, Degardin M, Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704.
  • Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–15.
  • Furusaka T, Kida A, Iizuka N, Kikuchi K, Tomita H. Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors. Auris Nasus Larynx 1986;13(Suppl 1):S135–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.